{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T11:27:31Z","timestamp":1764502051699,"version":"3.46.0"},"reference-count":53,"publisher":"Practical Medicine Publishing House","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Oncohematology"],"abstract":"<jats:p>Chemotherapy has been the main treatment option for multiple myeloma for several decades. However, a considerable increase in the life expectancy was observed in multiple myeloma patients when thalidomide, bortezomib and lenalidomide had been introduced into clinical practice. Nevertheless, the disease remains incurable and there is an unmet need in fundamentally new treatment methods. Elotuzumab is a humanized IgG1 monoclonal antibody that specifically targets SLAMF7, an antigen belonging to the signaling lymphocytic activation molecule family, with its high expression detected on myeloma cells. This review presents the mechanism of action of elotuzumab, preclinical data and the main clinical studies of this monoclonal antibody.<\/jats:p>","DOI":"10.21320\/2500-2139-2016-9-4-438-445","type":"journal-article","created":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T13:54:05Z","timestamp":1482155645000},"page":"438-445","source":"Crossref","is-referenced-by-count":0,"title":["Elotuzumab for Treatment of Multiple Myeloma (Literature Review)","\u042d\u043b\u043e\u0442\u0443\u0437\u0443\u043c\u0430\u0431 \u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b (\u043e\u0431\u0437\u043e\u0440 \u043b\u0438\u0442\u0435\u0440\u0430\u0442\u0443\u0440\u044b)"],"prefix":"10.21320","volume":"9","author":[{"given":"Ol\u2019ga Mikhailovna","family":"Votyakova","sequence":"first","affiliation":[{"name":"NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u043e\u043d\u043a\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u043d\u0430\u0443\u0447\u043d\u044b\u0439 \u0446\u0435\u043d\u0442\u0440 \u0438\u043c. \u041d.\u041d. \u0411\u043b\u043e\u0445\u0438\u043d\u0430\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041a\u0430\u0448\u0438\u0440\u0441\u043a\u043e\u0435 \u0448., \u0434. 24, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 115478"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8834","published-online":{"date-parts":[[2016,10,1]]},"reference":[{"key":"18274","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.12.027"},{"key":"18275","unstructured":"\u0421\u0442\u0430\u0442\u0438\u0441\u0442\u0438\u043a\u0430 \u0437\u043b\u043e\u043a\u0430\u0447\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0445 \u043d\u043e\u0432\u043e\u043e\u0431\u0440\u0430\u0437\u043e\u0432\u0430\u043d\u0438\u0439 \u0432 \u0420\u043e\u0441\u0441\u0438\u0438 \u0438 \u0441\u0442\u0440\u0430\u043d\u0430\u0445 \u0421\u041d\u0413 \u0432 2012 \u0433. \u041f\u043e\u0434 \u0440\u0435\u0434. \u041c.\u0418. \u0414\u0430\u0432\u044b\u0434\u043e\u0432\u0430, \u0415.\u041c. \u0410\u043a\u0441\u0435\u043b\u044c. \u041c.: \u0418\u0437\u0434\u0430\u0442\u0435\u043b\u044c\u0441\u043a\u0430\u044f \u0433\u0440\u0443\u043f\u043f\u0430 \u0420\u041e\u041d\u0426 \u0438\u043c. \u041d.\u041d. \u0411\u043b\u043e\u0445\u0438\u043d\u0430, 2014. 226 \u0441."},{"key":"18276","unstructured":"[Davydova MI, Aksel\u2019 EM, eds. Statistika zlokachestvennykh novoobrazovanii v Rossii i stranakh SNG v 2012 g. (Statistics of malignancies in Russia and CIS in) Moscow: Izdatel\u2019skaya gruppa RONTs im. N.N. Blokhina Publ.; 2014. 226 p. (In Russ)]"},{"key":"18277","unstructured":"EER Stat Fact Sheets: Myeloma, 2004\u20132010. [Internet] Available from: http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. (accessed 25.08.2014)."},{"key":"18278","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"18279","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.1964.1964"},{"key":"18280","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.03.005"},{"key":"18281","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"18282","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.15"},{"key":"18283","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"18284","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"18285","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1497"},{"key":"18286","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2015.1053866"},{"key":"18287","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06705.x"},{"key":"18288","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-91"},{"key":"18289","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"18290","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00481"},{"key":"18291","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.799130"},{"key":"18292","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-423202"},{"key":"18293","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.01.004"},{"key":"18294","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2013.04.004"},{"key":"18295","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181c51f0d"},{"key":"18296","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.847919"},{"key":"18297","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246"},{"key":"18298","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a002469"},{"key":"18299","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.10.5517"},{"key":"18300","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1693"},{"key":"18301","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1493-8"},{"key":"18302","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107292"},{"key":"18303","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.04.003"},{"key":"18304","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.56"},{"key":"18305","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.4061"},{"key":"18306","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1610-3"},{"key":"18307","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0483"},{"key":"18308","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360552"},{"key":"18309","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7069"},{"key":"18310","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.2649"},{"key":"18311","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601126602"},{"key":"18312","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.12.007"},{"key":"18313","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"18314","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"18315","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.147"},{"key":"18316","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694604"},{"key":"18317","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.302.302"},{"key":"18318","unstructured":"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT-1). [Internet] Available from: clinicaltrials.gow\/ct2\/show\/NCT01335399. (accessed 21.05.2016)."},{"key":"18319","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"18320","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.8508"},{"key":"18321","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08644.x"},{"key":"18322","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2010.152116"},{"key":"18323","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-2563"},{"key":"18324","unstructured":"US Food and Drug Administration. Elotuzumab [media release]. [Internet] Available from: http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm474719.htm. (accessed 22.05.2016)."},{"key":"18325","unstructured":"European commission Community register of medicinal products for human us\u0435. [Internet] Available from: http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1088.htm. (accessed 22.05.2016)."},{"key":"18326","unstructured":"NCCN Clinical Guidelines Version 3.2016. [Internet] Available from: https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma.pdf. (accessed 23.05.2016)."}],"container-title":["Clinical Oncohematology"],"original-title":[],"link":[{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/513\/475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/513\/475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T11:24:45Z","timestamp":1764501885000},"score":1,"resource":{"primary":{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/view\/513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,10,1]]}},"URL":"https:\/\/doi.org\/10.21320\/2500-2139-2016-9-4-438-445","relation":{},"ISSN":["2500-2139","1997-6933"],"issn-type":[{"type":"electronic","value":"2500-2139"},{"type":"print","value":"1997-6933"}],"subject":[],"published":{"date-parts":[[2016,10,1]]}}}